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Abstract
The hallmarks of many haematological malignancies and solid tumours are chromosomal translocations, which may lead to
gene fusions. Recently, next-generation sequencing techniques at the transcriptome level (RNA-Seq) have been used
to verify known and discover novel transcribed gene fusions. We present FusionFinder, a Perl-based software designed to
automate the discovery of candidate gene fusion partners from single-end (SE) or paired-end (PE) RNA-Seq read data.
FusionFinder was applied to data from a previously published analysis of the K562 chronic myeloid leukaemia (CML) cell
line. Using FusionFinder we successfully replicated the findings of this study and detected additional previously unreported
fusion genes in their dataset, which were confirmed experimentally. These included two isoforms of a fusion involving the
genes BRK1 and VHL, whose co-deletion has previously been associated with the prevalence and severity of renal-cell
carcinoma. FusionFinder is made freely available for non-commercial use and can be downloaded from the project website
(http://bioinformatics.childhealthresearch.org.au/software/fusionfinder/).
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Introduction
Translocations are rearrangements of regions of non-homolo-
gous chromosomes that can result in gene fusions as well as
amplifications, deletions and inversions. The critical role of
chromosomal abnormalities was recognised in the 1960s when
Nowell and Hungerford identified the Philadelphia chromosome
in CML [1]. This abnormality was later revealed to arise from a
translocation between chromosomes 9 and 22, resulting in the
BCR-ABL fusion gene [2,3]. Typically associated with haemato-
logical malignancies, gene fusions have more recently been linked
to solid tumours, including prostate, breast and lung cancers.
According to the May 2012 release (v59) of the Catalogue Of
Somatic Mutations In Cancer there are currently 7,732 fusions
known to be associated with benign and malignant tumours [4]
and many have been shown to play key roles in cancer initiation.
Gene fusions can also be linked to clinical outcome, for example,
the presence of the BCR-ABL1 fusion is a powerful predictor of
clinical outcome in paediatric acute lymphoblastic leukaemia.
Furthermore, gene fusions provide ideal therapeutic targets since
they create unique proteins not present in normal cells.
Systematic identification of gene fusions across cancer types is a
major undertaking. Historically, the focus has been on molecular
cytogenetic approaches, however, next-generation sequencing
(NGS) technologies are increasingly being used, as they are
considerably higher throughput and produce results at a much
higher resolution than techniques such as fluorescence in-situ
hybridization (FISH).
Transcriptome or RNA sequencing (RNA-Seq) [5] allows the
analysis of several aspects of genome transcription, providing
sequence data as well as the ability to detect alternative splicing
events and quantify gene expression levels. Since genetic
alterations identified by transcriptome sequencing are actively
expressed there is greater confidence that they may directly
contribute to the oncogenic phenotype rather than the many
mutations identified from genome sequencing for which transcrip-
tional status is not established. Further, as the transcriptome is
considerably smaller than the genome, the fold-coverage from a
typical sequencing run is much greater than for the whole genome
providing a greater opportunity to identify mutations expressed
even at very low levels. To date, transcriptome sequencing has
been used to comprehensively characterise gene fusions in
prostate, brain and breast cancer using both single-end (SE)
[6,7,8] and paired-end (PE) [9] variants of the RNA-Seq
technology.
A chromosomal breakpoint most commonly occurs within
intronic or intergenic regions but can on rare occasions occur
within exons [10,11]. In either case, when performing RNA-Seq
analysis, fusion transcript reads produced from sequencing
translocation events will contain exonic sequence from two
distinct genes. However, other biological mechanisms have been
reported in the literature that cloud this simple concept, namely
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transcription occurs when the RNA-polymerase continues
beyond the normal termination sequence and into an adjacent
gene, usually within 20 kb [12]. Novel fusion transcripts are then
generated by RNA-splicing from this larger pre-mRNA molecule.
Trans-splicing is a process whereby exons from two indepen-
dently processed transcripts from different locations in the
genome (even from different chromosomes) become spliced
together at the RNA level [13]. Complicating RNA-Seq analysis
further, random chimeric transcripts can also occur at the RNA
library preparation stage [14] when fragments of highly
expressed transcripts become randomly attached to fragments
from other genes. When RNA sequencing is performed, the
resultant reads from any of these phenomena can appear to
come from translocation-generated fusion transcripts as they too
contain exonic sequence from two distinct genes.
There is some debate regarding the suitability of SE versus PE
RNA-Seq approaches for the discovery of gene fusions. This is
because, while more costly, PE sequencing can provide a greater
depth of evidence for a gene fusion. With PE sequencing, reads are
usually mapped separately to a normal transcriptome or genome
reference to find pairs aligning to different genes, whilst with SE
data, only those reads that directly span a fusion boundary are
informative. However, recent advances in NGS platforms has
resulted in vast increases in coverage and read length meaning that
gene fusion boundaries are now adequately represented by SE
reads even at low levels of expression. A number of studies have
recently reported that the performance of SE sequencing is equal
to [8,15] and in some cases better than [16] PE, making SE
sequencing a more cost effective approach to the discovery of gene
fusions.
Previous work by Levin and colleagues [6] focussed on the
discovery of fusion transcripts using ‘‘targeted RNA-Seq’’, a
technique involving a combination of SE RNA-Seq and hybrid-
ization capture methods. Using this method they enriched their
initial sequencing data for 467 cancer-related genes in the CML
cell line K562. Following mapping of sequencing reads to a
reference transcriptome, candidate fusions were identified when
the first 30 bases of the read matched a different gene to the last 30
bases.
In this project we have extended and fully automated this type
of approach to develop the software FusionFinder. We applied our
software to the SE Illumina data arising from the work by Levin
and colleagues and, in addition to successfully replicating their
findings, we have identified and experimentally confirmed novel
fusion candidates expressed in K562 that may have functional
relevance for the disease.
Results
FusionFinder analyses FASTQ read data (of at least 50
nucleotides) to identify gene fusion candidates. This is achieved
by performing the following integrated analysis and filtering steps,
which are outlined in Box S1 and Figure 1. By default, all filters
described are enabled but some can be disabled with command
line options.
Step 1. Alignment of Full Length Reads Against a Normal
Coding Reference Transcriptome
The first step of the process (see Box S1) is to align the full length
reads (e.g. 100 nucleotide reads in the case of Illumina HiSeq data)
against a reference transcriptome containing only coding tran-
scripts to identify those reads that fail to match to a normal
dataset. We use Bowtie [17], to align the read data against this
reference transcriptome and produce Sequence Alignment/Map
(SAM) format [18] output, comprising one row per read where
each read has either a single transcript hit or fails to match
anything in the reference. The latter could be due to one of three
main reasons: (i) the normal reference transcriptome is not
comprehensive enough and does not contain the transcript to
which this read should match (i.e. a completely novel but genuine
non-fusion transcript or an expressed non-coding transcript); (ii)
the read is of poor quality and the alignment software could not
align it to any transcripts in the reference; (iii) the read overlaps the
exon-exon junction of a fusion transcript, the sequence for which is
understandably not in the reference transcriptome. It is these latter
sequences that are the target for FusionFinder.
A reference coding transcriptome that is compatible with our
analysis pipeline, can be obtained from our website [19,20]. The
references comprise all coding transcripts of all annotated genes
within recent versions of Ensembl [21].
Step 2. Creation of Pseudo Paired-end Reads
The next part of the process is to split each read with no
matching hits from Step 1 into two smaller sections, so we can
attempt to find sequences from different genes that match to each
section (see Box S1 and Figure 1). From all full length reads having
no hits in the reference transcriptome (i.e. reads that may
potentially match a fusion gene, see Figure 1A), a pair of FASTQ
‘‘pseudo PE reads’’ are derived with each pair comprising the first
n bases and the last n bases of the sequence of the full length read,
where n represents a proportion (0.4 by default but no greater than
0.5) of the length of the full length read (Figure 1A). It is important
to note that these pseudo PE reads retain the read ID of the parent
full length read and are simply appended with ‘/1’ or ‘/2’ to
distinguish each member of the pair (similar to PE reads), allowing
them to be later reunited. In addition, a line graph of the overall
quality of all full length reads is produced in this step.
Step 3. Alignment of Pseudo PE Reads against the
Coding Reference Transcriptome
The next step (see Box S1) is to align the pseudo PE reads
against the reference transcriptome to establish which, if any,
transcripts they align to. As in Step 1, we use Bowtie to align the
pseudo PE reads independently against the coding reference
transcriptome (Fig 1B). In Bowtie’s default mode, hits are
determined based on 100% identity between a read and a
transcript in the normal reference transcriptome over the first 28
bases of a read, while allowing for a 2 base mis-match. This acts as
a quality control step for the data, filtering out poor quality reads.
Step 4. Analysis and False-positive Filtering of the Pseudo
PE Read Results
The next steps of the process perform several stages of analysis
and filtering to narrow down the most likely candidate fusion
transcripts using the available evidence (see Box S1). Initially each
of the pseudo read pairs are reunited (based on their common ID)
and examined for which, if any, transcripts they hit. The first two
filters (Steps 4A & 4B) then discard data where the read pairs both
match the same gene or where either read of the pair does not
match anything in the reference transcriptome. If the read pairs hit
different genes, which we’ve termed a G1:G2 (i.e. Gene 1:Gene 2)
pair, the read pairs are stored in order to build up a body of
evidence for the existence of this G1:G2 pair (example provided in
Figure 1B). A G1:G2 pair can be regarded as a fusion candidate.
The third and fourth filters (Steps 4C & 4D) remove false positive
G1:G2 pairs where any read pairs hit either paralogous genes, or
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distinguish. These filters can be disabled using command line
options if required. In the next filter (Step 4E) the read pairs are
mapped back to the genome based on the coordinates where they
aligned to G1 and G2 respectively. By default, Bowtie reports a
single hit for a single read to a single transcript. Since transcript
coordinates cannot be directly compared (due to differential exon
usage between transcripts) all transcript/read alignment positions
are transposed to genomic coordinates, which are then compara-
ble. Using the canonical boundaries of each G1 or G2 exon, an
assessment is made of whether the mapped positions are realistic
given the size of the insert that should exist between them if the
two exons were indeed fused in a transcript. For example two
aligned 30mer pairs derived from a parent full length 76mer
should have 16 bases between them when their respective mapped
exon positions are assessed. Those read pairs mapping outside
these constraints are filtered. The implementation of this last filter
is responsible for eliminating many of the false positives including
those arising from the existence of potential chimeric fusion
artefacts in the RNA-Seq data. Finally (Step 4F) all pseudo PE
reads evidencing all G1:G2 fusions are again realigned using
Bowtie, firstly to the coding transcriptome reference and secondly
to a reference containing only non-coding transcripts. In these
alignment steps Bowtie is configured to allow all possible matches
in each reference. G1:G2 pairs are filtered if their pseudo PE reads
separately map to transcripts of the same gene in either reference.
This step removes false positives arising as the result of genes
sharing common exonic sequences. For example, the long
intergenic non-coding (Linc) RNA SUZ12P is comprised of exons
also found in both LPHN1 and SUZ12. Similarly, many unrelated
coding transcripts (some novel or un-annotated) contain common
exons (e.g. CCDC144A and USP32). Without a multi-mapping read
filter many of these examples would be incorrectly reported as
being transcript fusions. The multi-mapping step is performed at
this stage within FusionFinder (i.e. post-filtering, as opposed to
during the initial alignments in Step 1) since the required
computation time is significantly reduced with the smaller number
of candidate reads.
Step 5. Block Filtering and Identification of Fused Exons
and Isoforms from Candidate Fusion Transcripts
This stage combines the remaining read evidence for each
G1:G2 pair from Step 4 to identify the exons involved in the fusion
(see Box S1). Firstly (Step 5A) the genomic coordinates of each
mapped read are combined to construct ‘‘alignment blocks’’
comprising multiple overlapping reads that map to the same area
on G1 or G2 (see also Figure 1B). Each combination of blocks on
G1 and G2 are then searched for overlapping repeat elements as
indicated by RepeatMasker [22]. If the block on G1 overlaps the
same repeat element class as the block on G2, the block
combination is filtered out, as such reads are likely to represent
false positives. This filter (Step 5B) is optional and can be disabled
if required.
Figure 1. FusionFinder rationale. A) RNA-Seq produces millions of short reads, some of which will span the exon boundaries of hypothetical
fusion transcripts between Gene 1 and Gene 2. Two different fusion isoforms involving different exons are shown, left and right, along with a single
read that spans each breakpoint. Reads are split into smaller pseudo PE reads which can be aligned independently to a reference transcriptome. B)
Alignment of pseudo PE reads against the reference transcriptome. One of each pair aligns to an exon on Gene 1 and the other aligns to an exon on
Gene 2. Repeating this process for all other RNA-Seq reads creates ‘‘alignment blocks’’ from overlapping groups of aligned 59 and 39 pseudo PE reads
and their genomic coordinates. Multiple alignment blocks on either gene (as for Gene 1 in the example) provide evidence for the existence of
different isoforms of the fusion.
doi:10.1371/journal.pone.0039987.g001
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are then used to retrieve the Ensembl exon closest to this location
(Step 5C). As depicted in Figure 1B, these discrete blocks represent
the exons involved in the fusion. A single block on each of G1 and
G2 indicates a single isoform for this fusion. Multiple blocks
indicate multiple exon involvement and the existence of different
fusion isoforms consisting of different combinations of blocks from
G1 and G2.
Next, the number of pseudo PE reads providing evidence for
each G1:G2 pair following filtering is determined (Step 5D).
Here the user can opt to filter G1:G2 pairs that are not
evidenced by at least a minimum number of pseudo PE reads.
Restricting results to higher numbers of reads reduces the
likelihood of false positives, while the acceptance of smaller read
numbers will capture those fusion transcripts expressed at lower
levels.
Finally (Step 5E), categories are assigned to each G1:G2 pair
based on the given evidence as follows:
1. Intrachromosomal - Genes originate from the same chromo-
some
2. Interchromosomal - Genes originate from different chromo-
somes
3. Potential Readthrough - Genes on the same chromosome and
strand and ,=20 kb apart
4. Inversion - Genes on the same chromosome but different
strands
Output Files
Four main output files are produced. The first is a summary
file, which contains a ranked list of fusion candidates based on
their evidence strength (total number of sequence reads). The file
provides the Ensembl and HUGO (Human Genome Organiza-
tion) Gene Nomenclature Committee (HGNC) common name
identifiers for G1 and G2, the number of blocks on each gene,
an indication of how many isoforms exist for each G1:G2 pair
and the category of fusion indicated by the pair. The second file
gives the full details for each isoform of G1 and G2 and includes
the genomic coordinates of the alignment blocks on G1 and G2,
and their respective corresponding Ensembl exon IDs. For each
isoform of a candidate fusion, the remaining two files provide (i)
the sequences of the pseudo PE reads and the corresponding full
length parent read and (ii) a forward three-frame translation of
the fused nucleotide sequence of the two exons implicated in the
candidate fusion. While FusionFinder is running, the software
outputs all filtered read data to a separate file that contains a flag
denoting the stage at which each read was filtered. In addition,
statistics are produced detailing the raw numbers of reads that
have been filtered at various stages of the algorithm and those
remaining that provide the evidence for the fusion candidates
contained in the summary file.
Further Investigation of Fusion Candidates
Using the common names of a G1:G2 pair of interest one can
use FusionFinder to generate alignments to assist in the
experimental confirmation of the candidate by RT-PCR. These
alignments detail a) where the pseudo PE reads align to G1 and
G2 and b) the exact location of the transcript breakpoint on the
aligned parent reads (an example of this alignment is given in
Figure 2).
Software Implementation
FusionFinder has been tested on various versions of Perl from
5.10 onwards and makes extensive use of the BioPerl [23] and
Ensembl API [21] libraries, which are required to be installed
locally with the software. Several other Perl libraries are also
required (standard libraries available in the Comprehensive Perl
Archive Network) that are detailed further in the software manual
available from the project website [19,20]. We have comprehen-
sively tested FusionFinder on 64-bit Linux, but it can be run on
both Windows and MacOS platforms provided Perl and the
aforementioned dependencies are installed. FusionFinder requires
access to an Ensembl database (ideally a locally installed) to
perform some sections of the identification process.
The commands to run FusionFinder are described in the online
user manual available from the project website [19,20]. The
source code for FusionFinder is made freely available from our
website under the GNU General Public License (GPL).
Application of FusionFinder to a Published RNA-Seq
Dataset
We applied FusionFinder to data arising from work by Levin
and colleagues [6] who performed a targeted RNA-Seq analysis of
the K562 CML cell line. They generated sequencing data both
pre- and post-enrichment for 467 cancer-related genes. We used
the dataset representing the sequencing produced post-enrich-
ment, which consisted of 14 million 76mer SE reads in FASTQ
Figure 2. Identification of the transcript breakpoint in each PRIM1:NACA isoform. Alignments of the full length 76mer reads providing
evidence for the two isoforms of PRIM1:NACA (i.e. as originally identified by Levin et al, top, and the novel isoform identified by FusionFinder, bottom)
against the last 30 bases of the implicated PRIM1 (G1) exon and the first 30 bases of the NACA (G2) exon. The transcript breakpoint can be clearly seen
where the PRIM1 exon ends and the NACA exon begins. Also displayed is an in-frame translation of the G1 exon from wild type PRIM1, running into
the fused NACA exon. Both isoforms retain an open reading frame despite different exon usage.
doi:10.1371/journal.pone.0039987.g002
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generated 30mer pseudo PE reads and searched for candidates
that were evidenced by $4 pseudo PE reads. We used a coding
transcriptome reference containing only those Ensembl transcripts
with a known translation and source data from a local installation
of Ensembl (release 62 - April 2011). All read alignments were
performed with Bowtie (version 0.12.7), allowing for a 2 base
mismatch.
Our analysis produced a final list of 9 fusion candidates. Table 1
gives the details of these candidates as presented in the
FusionFinder summary file. Table 2 shows the details found in
the FusionFinder isoforms file for each of the fusion candidates
from Table 1 that were previously reported by Levin et al.
Replication of the Levin Results
Using a similar (but not fully automated) technique to that
presented here, Levin and colleagues confirmed the findings of
Maher et al [9], who also analysed the K562 cell line using a PE
sequencing approach and observed the fusions BCR:ABL1 and
NUP214:XKR3, fusions 1 and 2 in Table 1. In addition to these,
when analysing the enriched dataset, Levin et al. reported the
previously unobserved fusion transcripts listed at 3, 4, 5 and 7 in
Table 1. Overall they reported four isoforms of the NUP214:XKR3
fusion (involving specific combinations of exons 29 and 27 of
NUP214 and exons 2, 3 and 4 of XKR3) and four isoforms of the
RCC1:PICALM fusion.
Within our candidates, we observed all six fusion events
reported by Levin and colleagues (highlighted in Table 1). These
included the three isoforms of NUP214:XKR3 involving exon 29 of
NUP214 and all four isoforms of RCC1:PICALM. The fourth
isoform of NUP214:XKR3 involving exon 27 of NUP214 was found
in a separate analysis using a value of 0.2 when generating the 3’
pseudo PE reads (data not shown). Importantly, FusionFinder also
reported that due to their genomic proximity, candidates listed as
3, 5 and 7 in Table 1 are potential read-through transcripts as
described elsewhere [16].
Additional Findings
In addition to those fusions found by Levin et al., FusionFinder
generated evidence for three other gene fusions expressed in the
K562 cell line (Table 1, non-shaded) as well as a second isoform of
the PRIM1:NACA fusion (see Table 2). These new candidates are
ACCS:EXT2, C3orf10:VHL and CEP170:RAD51L1 the first two
each having multiple associated isoforms (Table 1).
Figure 2 shows the alignment for both identified isoforms of
PRIM1:NACA (i.e. the original isoform identified by Levin et al.,
and the novel isoform identified by FusionFinder) and an in-frame
translation for the region 30 bases upstream and downstream of
the transcript breakpoint. In wild type PRIM1, a stop codon lies
within the exon downstream of the implicated transcript break-
point. However, in both fusion isoforms an open reading frame is
retained through the fused NACA exon, therefore generating a
sequence coding for a novel fusion peptide.
Experimental Confirmation of Novel Fusions
Using RT-PCR and Sanger sequencing we experimentally
confirmed the existence of two of the three novel fusions (8 and 9
in Table 1) as well as the novel isoform of PRIM1:NACA using
RNA extracted from the commercially available K562 cell line
(Figure 3). In addition we confirmed that the sequence at the
transcript breakpoints of the previously identified fusions
BCR:ABL1 and SLC29A1:HSP90AB1 were correctly predicted by
FusionFinder. At least one predicted isoform of each confirmed
novel fusion was detectable in our particular K562 cell line.
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39987Failure to detect every isoform of each predicted gene fusion is
attributable to fact that we did not employ the targeted-
enrichment protocol used by Levin et al prior to experimental
confirmation, which would dramatically increase the representa-
tion of these transcripts within the RNA pool.
Comparison to Existing Software on Real and
Simulated Data
Recently published software for the analysis of RNA-Seq data
for gene fusions include FusionMap [16], FusionSeq [24],
FusionHunter [25], deFuse [26] and Tophat-Fusion [15]. Of
these, both FusionMap and Tophat-Fusion can process SE read
data. FusionMap uses a similar strategy to FusionFinder by
splitting reads into smaller sections and finding fusion candidates
where sections align to different genes on an annotated genomic
reference prior to filtering. Tophat-Fusion uses to a two stage
process of firstly aligning reads with a modified version of the
spliced alignment software Tophat [27] to a genomic reference
before secondly performing a post processing step to overlay
annotation and perform filtering.
To compare the performance of FusionFinder with FusionMap
and Tophat-Fusion we have run a full analysis with all three tools
using the Levin dataset. For this dataset, comprising 14 million
76mer reads, a complete analysis with FusionFinder took
approximately 3.1 hours on a single 2.4 GHz core of a multi-
core AMD server with a peak memory usage of 1.8GB and using
data from a local Ensembl (release 62) mirror. FusionMap (version
2012-03-03) with comparable parameters (a=25, b=1, G=2)
and preloaded reference data running the same analysis using
Mono (version 2.10.8) under 64-bit linux, again on a single
2.4 GHz core, took 2.1 hours to complete and at its peak
consumed 7.2 GB memory. Tophat-Fusion with comparable
parameters (alignment phase: –fusion-min-dist 10000 and post-
processing: –num-fusion-reads 4–num-fusion-pairs 0–num-fusion-
both 4) and reference data on the same platform took 15 hours to
complete and consumed 9.6 GB memory at its peak during the
post-processing step. Although the run time for FusionFinder is
slightly slower than FusionMap on a single core both are
considerably faster than Tophat-Fusion. In addition FusionFinder
consumes far less memory under a Linux operating system than
both FusionMap and Tophat-Fusion. It should be noted that both
FusionMap and Tophat-Fusion can be run on multiple CPU cores
and with the same dataset and parameters but with 5 CPU cores,
the analysis took 0.8 hours and 4.5 hours respectively. Similarly
Bowtie can be run on multiple CPU cores and using 5 cores for the
alignment steps in the FusionFinder protocol improves the total
analysis time to 2.4 hours. We are currently working on a fully
multithreaded version of FusionFinder. These data are summa-
rised in Table 3 and a detailed breakdown of resources used by
FusionFinder at each step of the protocol can be found in Table
S4.
In line with previous reports [16] our analysis of the Levin
dataset with FusionMap confirmed the findings of Levin et al. and
reported an additional 57 candidates in this dataset. In compar-
ison, Tophat-Fusion reported 12 candidate fusions but did not
successfully identify all those reported by Levin et al or the
additional candidates reported by FusionFinder, even when we
allowed for the detection of the read-through transcripts we
observed. Tophat-Fusion only reported two of the three isoforms
of NUP214:XKR3 reported by FusionFinder and did not report
CEP170:RAD51L1 but did report an additional isoform of
BCR:ABL1 which was not reported by FusionFinder or Fusion-
Map. The results of these analyses are presented in Table S1 a
and b.
To further compare the performance of each software we
generated a simulated dataset of approximately 13.5 million SE 75
nucleotide reads (see Methods). The dataset contained normal
background reads and ‘‘fusion reads’’ representing the transcript
breakpoint of 55 fusion transcripts generated at random (see Table
S2a). The dataset simulated fusions designed to represent both
high and low levels of expression with read numbers per fusion
transcript ranging from 1 – 295. We ran FusionFinder, FusionMap
and Tophat-Fusion against this dataset. FusionFinder was run with
default parameters, generating 30mer pseudo PE reads. Fusion-
Map was run with comparable parameters (a=30, b=1, G=2,
MinimalHit=1), though we note that in order for FusionMap to
Figure 3. RT-PCR validation of the fusion candidates. Primers were designed around the individual fusion breakpoints and cDNA was
synthesised using gene-specific primers. Products were successfully amplified for the following fusion isoforms; BCR:ABL (380 bp, lane 1), PRIM1:NACA
isoform 1 (400 bp, lane 2), PRIM1:NACA isoform 2 (340 bp, lane 3), C3orf10:VHL isoform 2 (340 bp, lane 6), ACCS:EXT2 isoform 3 (230 bp, lane 9) and
SLC29A1:HSP90AB1 (340 bp, lane 10). No product could be amplified from CEP170:RAD51L1 (lane 4), C3orf10:VHL isoform 1 (lane 5), ACCS:EXT2 isoform
1o rACCS:EXT isoform 2 (lanes 7 and 8). The corresponding negative controls for each reaction are in the lanes proceeding each reaction. All detected
fusion products were validated by Sanger sequencing.
doi:10.1371/journal.pone.0039987.g003
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e39987detect any simulated fusions it was necessary to alter the
MinimalRescuedReadNumber parameter to 0. Tophat-Fusion
was also run using comparable parameters for the post-processing
step of the protocol (–num-fusion-reads 1–num-fusion-pairs 0–
num-fusion-both 1). Sensitivity and Positive Predictive Values
(PPV) were then calculated for the simulated dataset to assess the
ability of each software to accurately detect simulated fusion genes
(see Methods). Table 4 summarises the overall results of this
analysis whilst a plot of these data is shown in Figure 4. The raw
results from each software can be found in Tables S2 b, c and d.
The performance measures were calculated on subgroups of fusion
genes where subgroups were selected based on the number of
reads (i) evidencing the fusion genes predicted by each software.
For example, the point marked at 100 on the x axis of Figure 4
shows performance measures for all predicted fusion genes that
were found to be evidenced by 100 or more reads.
Among the fusion gene predictions made by each software are
what we have termed ‘‘synonymous fusions’’. These are where at
least one of the identified gene partners has been inaccurately
predicted because it shares high sequence similarity with the
expected partner gene, possibly because it is a member of the same
gene family (for example, an S100A3:SULT1A4 fusion may be
detected as an S100A3:SULT1A3 fusion). Although the informed
researcher would frequently be able to distinguish these fusions by
visual comparison with other candidates in the output files, in our
assessment of sensitivity and PPV such synonymous fusions were
considered to be false positives to provide the most stringent
assessment of each software.
It can be seen from Figure 4 and Table 4 that FusionFinder
shows greater sensitivity and generally greater PPV than
FusionMap in the detection of our simulated fusion genes.
Figure 4 also shows that FusionFinder compares favourably
against Tophat-Fusion with an overall greater sensitivity and a
comparable PPV. With regard to the overall sensitivity in Table 4,
FusionFinder detected 87% of the 55 simulated fusion genes,
FusionMap reported 58% and Tophat-Fusion reported 64%.
Importantly, FusionFinder and Tophat-Fusion only detected 15
and 5 false positives respectively (some of which were synonymous
fusions - see Table S2 b, c and d) giving them a comparable PPV.
In contrast FusionMap reported 582 false positives, which
represents 95% of the returned results respectively (Table 4). This
has a considerable effect on the PPV in Figure 4 at low read levels
with FusionMap remaining significantly lower than both Fusion-
Finder and Tophat-Fusion. Consequently, in the case of
FusionMap the user is returned a large list of potential fusion
genes consisting primarily of false positives. In contrast, the
candidates reported by FusionFinder will be more robust and
more likely to be confirmed experimentally.
For two of the fifty-five simulated fusions, the partner genes
contained repeats of the same class at the transcript breakpoint.
These gene fusions were detected by FusionFinder but due to the
RepeatMask filter, were subsequently filtered. However, both of
these appeared in the FusionMap results, suggesting that
FusionMap does not take the presence of repeats in to account.
This could explain the occurrence of so many false positives in
FusionMap’s results. Both of these simulated fusions were also
filtered by Tophat-Fusion.
It should be noted that when both FusionMap and Tophat-
Fusion detected a simulated fusion gene they consistently detected
all simulated fusion reads, however although FusionFinder
detected more simulated fusion genes it did not consistently detect
all fusion reads. This is because, FusionFinder analyses data from
an alignment using Bowtie’s default parameters which does not
provide results for multi-mapping reads. This means that given
two genes from the same family, sharing high sequence identity, a
read has an equal chance of hitting either of these genes. As a
result, the expected fusion reads are distributed between all
synonymous fusions. We are working on a method to analyse
alignments of multi-mapping reads, which will significantly
increase the numbers of reads detected.
Table 3. Performance comparison of FusionFinder, FusionMap and Tophat-Fusion in an analysis of the Levin dataset.
FusionFinder FusionMap Tophat-Fusion
Total time taken - single core (hrs) 3.1 2.1 15.0
Total time taken - 5 cores (hrs) 2.4 0.8 4.5
Peak Memory - single core (GB) 1.8 7.2 9.6
Data based on the analysis of the Levin dataset comprising 14 million 76 mer reads, using either a single 2.4 GHz core or 5 cores of a 64-bit linux machine with multiple
AMD Opteron 8431 CPUs and 32GB memory. The parameters used for each analysis are in the main text and the raw results for each analysis can be found in Table1
and Tables S1 a and b.
doi:10.1371/journal.pone.0039987.t003
Table 4. Summary of the overall comparative performance of FusionFinder, FusionMap and Tophat-Fusion on a simulated dataset.
Sensitivity PPV
True positive
fusions
True positive
reads
False positive
fusions False positive reads
FusionFinder 0.87 0.76 48 2937 15 433
FusionMap 0.58 0.05 32 2065 582 7045
Tophat-Fusion 0.64 0.88 35 3120 5 446
A total of 55 fusion genes were simulated. Sensitivity and PPV measures were compiled from predicted fusion genes evidenced by 1 read or more (i.e. all data). True
positive fusions/reads relate to the accurate prediction of simulated fusions whereas false positive fusions/reads relate to all other predictions including synonymous
fusions. For FusionFinder, all false positive genes and consequently all false positive reads were from synonymous fusions (see Table S2b). FusionFinder detects more
simulated fusions and significantly fewer false positives than FusionMap with consistently greater sensitivity and PPV. FusionFinder showed a higher sensitivity and
comparable PPV to Tophat-Fusion.
doi:10.1371/journal.pone.0039987.t004
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While FusionFinder is more suited to the analysis of SE data, it
can also be used to analyse PE data, by considering each PE reads
file as a separate SE reads file. We applied FusionFinder to PE
RNA-Seq data from the MCF-7 breast cancer cell line as
previously described [28] and also analysed by the authors of
Tophat-Fusion [15]. This dataset comprises approximately 17
million 50 bp PE reads. Table 5 shows the results of an analysis of
this data with FusionFinder using default parameters but creating
25 bp pseudo PE reads and searching for candidates with at least
two reads evidencing them. We found seven fusions, six of which
have been previously reported [28,29]. Only three of these fusions
were found by Tophat-Fusion [15].
Discussion
FusionFinder is a Perl based software suite designed for the
discovery of fusion transcripts and their isoforms. We have
demonstrated the use of FusionFinder by applying it to publicly
available SE (the Levin dataset) and PE (MCF-7) data. In the case
of the Levin dataset we successfully replicated previously published
findings (including the discovery of an additional isoform of the
previously reported PRIM1:NACA fusion, Figure 2) and revealed
three other candidates for further study. In total there were 9
fusion candidates passing all filters. The Levin dataset represents a
targeted RNA-Seq approach wherein 467 cancer-related genes
were representationally enriched. As expected, at least one or both
of the genes implicated in each of our fusion candidates were
enriched for by Levin et al. Aside from the six fusion transcripts
reported by Levin et al., the three additional fusions we have
identified with FusionFinder are also of biological interest:
C3orf10:VHL or BRK1:VHL (Table 1, #8) - VHL is a tumour
suppressor gene deleted in von Hippel Lindau disease, an
autosomal dominant familial cancer syndrome that can give rise
to pheochromocytoma and tumours of the kidney, central nervous
system, pancreas, retina and epididymis. The BRK1 gene (BRICK1,
C3orf10 or HSPC300) lies upstream of VHL on chromsome 17 and
is involved in the branched nucleation of actin fibres. Although no
fusions of the two genes have to date been reported, co-deletion of
BRK1 has been shown to alter the prevalence and severity of renal-
cell carcinoma in patients with VHL deletion [30,31]. Such co-
deletion has been attributed to Alu-mediated recombination since
the genes lie in a region of high Alu density [30] and it is likely that
gene fusion could occur by a similar mechanism with deletion of
the intergenic region. This is consistent with the transcript
breakpoint in isoform 2, which appears to involve an intra-exonic
break in the C3orf10 gene (sequences available in File S1), arguing
against an RNA-splicing mechanism. The oncogenic effect of a
fusion between these genes is not known but their co-operating
role in the development of renal cell carcinoma suggests that the
existence of this fusion transcript in the K562 CML cell line is
likely to be functionally relevant. The expression of one of the
isoforms of this fusion was confirmed by RT-PCR in our K562 cell
line.
ACCS:EXT2 (Table 1, #9) - EXT2 is a tumour supressor gene
implicated in multiple osteochondroma [32], with the gene being
affected by a wide-range of mutations including frameshift and
splice-site mutations. The proximity of the ACCS and EXT2 genes
suggests that this potential fusion may result from read-through
Figure 4. Comparison of sensitivity and PPV for FusionFinder, FusionMap and Tophat-Fusion. To compare the sensitivity and PPV of
FusionFinder, FusionMap and Tophat-Fusion to detect fusion genes, each software was used to analyse a randomly generated dataset simulating
normal genes and 55 fusion genes. Calculations of sensitivity and PPV were made for subgroups of the results based on the number of reads
evidencing the fusion genes predicted by each software. FusionFinder shows consistently higher sensitivity than both FusionMap and Tophat-Fusion
and shows a generally higher PPV than FusionMap and similar PPV to Tophat-Fusion.
doi:10.1371/journal.pone.0039987.g004
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with PRIM1:NACA (Table 1, #4) and a number of others from
Table 1. Again, expression of this gene fusion was confirmed by
RT-PCR in our K562 cell line.
CEP170:RAD51L1 (Table 1, #6) – RAD51L1 is a DNA repair
gene, and is a known translocation partner in a series of benign
solid tumours [33]. Although this fusion was not confirmed
experimentally in our K562 cell line, this is likely due to the fact
that we did not perform the enrichment protocol employed by
Levin and colleagues prior to experimental confirmation.
The results of our software comparison clearly demonstrate the
utility of FusionFinder versus two other existing methods. As well
as more consistently predicting gene fusions, FusionFinder
provides more detailed sequence based output to assist in the
experimental confirmation of fusion candidates. Using the three
frame translation of the area around the predicted transcript
breakpoint one can quickly establish whether an open reading
frame exists across the fused exons. Furthermore, the alignments
produced by FusionFinder provide a more detailed picture of the
context of the fusion, which is valuable information when seeking
experimental confirmation. In addition to demonstrating that
FusionFinder can detect gene fusions in enriched SE data (Levin
dataset) and simulated SE data we have also shown the detection
of gene fusions in publicly available PE data (MCF-7). Further-
more we have applied FusionFinder to our own in-house RNA-
Seq data and have characterised a novel fusion transcript
expressed in a rare paediatric carcinoma (manuscript under
review).
A few assumptions exist that must be considered when using
FusionFinder, although these would apply to most software of this
nature aimed at analysing RNA-Seq data. Firstly, FusionFinder
will only detect transcribed gene fusions because RNA-Seq only
sequences at the transcript level. Secondly, RNA-Seq is a
quantitative technology and transcripts that are more highly
expressed are sequenced at higher coverage, meaning that
transcripts expressed at lower levels will be harder to detect.
Despite this caveat, those that are represented at low levels, even
down to a single read, will be pulled out of the sea of false positives
by the extensive logical filtering within FusionFinder. Thirdly,
FusionFinder cannot distinguish between a physical fusion, RNA
trans-splicing or read-through transcription. Fourthly, FusionFin-
der is designed to detect fusions occurring at canonical exon
junctions. Therefore it will not typically detect fusions involving
intra-exon breakpoints, which are relatively rare [10,11]. However
it should be noted that FusionFinder was able to detect the
experimentally confirmed C3orf10:VHL (isoform 2) fusion, align-
ments for which implicate an intra-exon break. An explanation for
this particular case can be found in File S1. Finally, it is essential
that the transcriptome reference library is comprehensive enough
to reliably capture all known transcripts. The reference libraries
we provide comprise annotated transcripts contained within
Ensembl and are updated in line with new builds of Ensembl.
Using reference data from Ensembl has an additional advantage in
that when a new Ensembl build is released it is a very straight
forward process for the user to download a new reference dataset
from our website [19,20], update their Ensembl API and point to
the new build. In doing so the user always has access to the most
current reference annotation.
The candidates identified by FusionFinder are predictions based
on sequence evidence and laboratory confirmation is required to
determine whether or not a transcribed fusion gene will be
functional. The alignments generated by FusionFinder assist in this
process by providing the sequence of the fusion candidate at the
point of the transcript breakpoint and also provide details
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frame. Once the sequence of the fused exons is known, it is
possible to generate predicted models of the full fusion transcript
and subsequently assess expression levels using the algorithms
provided within software such as Cufflinks [34] and EdgeR [35].
Whilst FusionFinder identifies any expressed fusion transcripts
from the sample under investigation, researchers must of course
consider cellular heterogeneity in their interpretation of the data,
and the possibility that signals may arise from multiple clones (or
different cell types) within the specimen.
As next-generation sequencing technologies become more
affordable, so the number of studies using this technology to
discover fusion transcripts will increase. There is a great need for
adequate analysis software that can rapidly interrogate such large
amounts of data to reveal the patterns therein. FusionFinder
provides a logical and flexible software solution to this end that will
facilitate the automated discovery of fusion transcripts in RNA-
Seq data. FusionFinder has not only validated the fusion
transcripts previously reported for the K562 CML cell line but
has also identified novel candidate fusions. Of these, BRK1:VHL
represents the fusion of two genes that have previously been shown
to co-operate in the development of renal cell carcinoma. This is
the first description of a potential direct fusion between these two
genes.
Materials and Methods
Experimental Confirmation
The validation of ten isoforms from six of the fusion genes
identified by FusionFinder was performed by Sanger sequencing of
RT-PCR products. Total RNA from K562 ([36] a gift from Prof.
GR Shellam, University of Western Australia) was reverse
transcribed using gene specific primers (individual details for
successful primers can be found in Table S3) and Omniscript RT
(Qiagen) according to the manufacturer’s instructions. RT-PCR
products were then amplified using GoTaqH Flexi DNA
polymerase (Promega). The amplification conditions were as
follows: initial denaturation at 95uC for 2 minutes, followed by 35
cycles of 30 seconds at 95uC, 30 seconds at 60uC and 45 seconds at
72uC, with a final extension step of 72uC for 5 minutes. PCR
products were gel extracted and purified using a QIAquick Gel
Extraction Kit (Qiagen) and were then subject to Sanger
Sequencing using BigDyeH Terminator V3.1 (Applied Biosystems
- ABI). The sequencing amplification conditions were as follows:
initial denaturation at 96uC for 1 min, followed by 35 cycles of 10
seconds at 96uC, 5 seconds at 50uC and 4 minutes at 70uC.
Samples were purified and then sequenced on an ABI 3130 xl
machine. Sequences were aligned to the original fusion transcript
sequences for validation.
Generation of Simulated Datasets
To produce a simulated dataset that was representative of a real
SE RNA-Seq run, we firstly examined an in house RNA-Seq
dataset to establish what typical proportion of all possible Ensembl
genes and transcripts were represented and the distribution of
reads representing them. Using these parameters we then wrote a
Perl script that randomly selected transcripts from Ensembl and
through sampling from our known read distribution, a random
number of reads were then generated across the full length of each
selected transcript. During this process, pairs of transcripts from
different genes were selected at random to be used as fusion
transcripts. The sequences of a single exon from each fusion
transcript were then combined and a random number of reads
were generated across the simulated fusion breakpoint, ensuring
that each read contained at least 30 bases of either exon. All
normal and fusion reads were generated in the forward orientation
with a random number being reversed and complemented to
represent the fact either strand of a cDNA fragment may be
sequenced. In addition to the normal and fusion reads, 10,000
random sequence reads were generated to represent reads of poor
quality sequence.
Calculation of Performance Measures
For our comparison of software performance, sensitivity was
defined as the proportion of correctly identified fusion genes and
PPV as the proportion of identified fusion genes that are true
simulated fusion genes. These performance measures are defined
as follows:
Sensitivityi~
TP
TPzFN
Positive Predictive Valuei~
TP
TPzFP
where TP (True Positive) is the number of correctly identified
fusion genes, FN (False Negative) is the number of fusion genes
that are not correctly identified and FP (False Positive) is the
number of genes incorrectly identified as fusion genes. The
number of reads evidencing the fusion genes is denoted by i and in
our simulations ranged from 1 to 295.
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